Endobronchial Ultrasound Biopsy Market is predicted to reach USD 1.01 billion at a CAGR of 5.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Endobronchial Ultrasound Biopsy Market”.

The Endobronchial Ultrasound Biopsy market is estimated to register a CAGR of 5.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Endobronchial Ultrasound Biopsy market— Olympus Corporation, Medtronic, Cook Medical, CONMED Corporation, CLINODEVICE, Medi-Globe GmbH, and Boston Scientific Corporation.

Endobronchial Ultrasound Biopsy Market Highlights

The global Endobronchial Ultrasound Biopsy market is accounted to register a CAGR of 5.00% during the forecast period and is estimated to reach USD 1.01 billion by 2032.

The worldwide endobronchial ultrasound biopsy market is expected to expand at a significant CAGR throughout the forecast period. There is a sudden shift in the world's climate due to the rising incidence of lung cancer. The potential for sedation-related problems, including hypoxemia and hypotension during bronchoscopy operations, is a major obstacle to the anticipated expansion of the global endobronchial ultrasound biopsy market.

Segment Analysis

The global Endobronchial Ultrasound Biopsy market has been segmented based on Product, Application, and End-user.

On the basis of Product, the market is segmented into Biopsy Forceps, Cytology Brushes, Biopsy Needles, Transbronchial Aspiration Needles, Spray Catheters, and Others. The transbronchial aspiration needles category had the most share in 2023. Transbronchial aspiration needles, which are situated near the endobronchial tree, are used to remove tissue from lesions in the lung, hilar, or mediastinum. An evaluation of the lung mass or lymph nodes during a bronchoscopy helps to place the desired lesion.

Based on Application, the global Endobronchial Ultrasound Biopsy market has been segmented into Cancer Diagnosis, Infection Diagnosis, and Others. In 2023, the Cancer Diagnosis sector maintained its top market position. The growing need for minimally invasive medical procedures and the growing use of these procedures for disease diagnosis by interventional radiologists and diagnostic departments of healthcare facilities (such as medical clinics and diagnostic centers) are factors driving market expansion.

Based on End-user, the global Endobronchial Ultrasound Biopsy market has been segmented into Hospitals, Ambulatory Surgical Centers, Cancer Specialty Clinics, Diagnostics Centers, and Others. Hospitals are projected to maintain their top market position until 2023. The dominance of the hospitals segment may be attributed to an increasing trend in the number of government and private hospitals in emerging countries like China and India, as well as an increase in the number of EBUS operations conducted in hospitals.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Endobronchial Ultrasound Biopsy Market Research Report

Regional Analysis

The global Endobronchial Ultrasound Biopsy market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Endobronchial Ultrasound Biopsy market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Endobronchial Ultrasound Biopsy market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Endobronchial Ultrasound Biopsy market comprises the Middle East, Africa, and Latin America.

Regionally, endobronchial ultrasound biopsy remained the product of choice in North America. Given the continuing need for technical improvement in healthcare, manufacturing enterprises headquartered in North America may have an opportunity to improve their operations when favorable conditions arise. In order to diagnose lung cancer, endobronchial ultrasonography biopsies are in high demand. This is due to the fact that North America's rapid economic development has attracted a large number of manufacturers and suppliers. New diagnostic and treatment technologies, a booming pharmaceutical industry in the area, and a more health-conscious and financially stable populace are all factors that might boost this sector's market potential.

Moreover, there will likely be some modest growth in the European market in the next years due to factors like new technologies and an increase in lung cancer cases. The FDA approved the EBUS biopsy device because of its unique use in the detection and treatment of lung cancer. We expect this endeavor to support the growth of the market for this particular subject. British endobronchial ultrasound biopsies are expected to outsell all of Europe's competitors in the near future, thanks to the rising popularity of non-invasive diagnostic procedures in the healthcare industry.

Additionally, due to factors such as the growing number of improved diagnostic tools, healthcare infrastructure investments, and growing lung cancer cases, the Asia-Pacific market is expected to see the fastest revenue growth rate (CAGR) over the projection period. Consistent expansion is predicted in the industry, driven by increased demand for healthcare services and large populations in emerging nations like India and China. Potential drivers of the expected growth in this industry might include government initiatives promoting early diagnosis and treatment of lung cancer.

With that said, the rest of the endobronchial ultrasound biopsy market is made up of regions in Africa, Latin America, and the Middle East. With more and more people learning about the advantages of ultrasound-guided biopsy procedures, their use and acceptance are on the rise in the medical community.

Key Findings of the Study

• The global Endobronchial Ultrasound Biopsy market is expected to reach USD 1.01 billion by 2032, at a CAGR of 5.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market owing to the increasing prevalence of lung cancer, heightened utilization of advanced diagnostic techniques, and the expansion of healthcare infrastructure.


• Based on End-user, the Hospitals segment was attributed to holding the largest market in 2023.


• Olympus Corporation, Medtronic, Cook Medical, CONMED Corporation, CLINODEVICE, Medi-Globe GmbH, and Boston Scientific Corporation are the key market players.